Ozempic vs Mounjaro comes down to two different drugs approved for the same job: Ozempic is semaglutide and Mounjaro is tirzepatide, both once-weekly injections for type 2 diabetes. Mounjaro is the dual GLP-1/GIP drug and tends to lower blood sugar and body weight more, while Ozempic has the longer track record and broader real-world use. Neither is FDA-approved for weight loss on its own (those are Wegovy and Zepbound, the same molecules), but both are widely prescribed off-label for weight, which is why this comparison matters. Here is Ozempic vs Mounjaro on blood sugar, weight, cost, and side effects, side by side.
Ozempic vs Mounjaro at a glance
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug class | GLP-1 agonist | Dual GLP-1 / GIP agonist |
| Maker | Novo Nordisk | Eli Lilly |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes |
| A1c reduction (head-to-head) | ~1.9% (semaglutide 1 mg) | ~2.3% (tirzepatide 15 mg) |
| Weight loss (in diabetes trials) | ~6 kg | ~11 kg |
| List price / month | ~$997 | ~$1,069 |
| Weight-loss twin | Wegovy | Zepbound |
The key difference: two different molecules
Like every Ozempic comparison, the brand names hide the real story. Ozempic is semaglutide, which activates the GLP-1 receptor. Mounjaro is tirzepatide, which activates both the GLP-1 and the GIP receptor. That extra target is the leading explanation for why Mounjaro tends to lower both blood sugar and weight more in studies. We unpack the science in how tirzepatide works and compare the molecules in semaglutide vs tirzepatide.
Blood sugar: Mounjaro edges ahead
Both drugs are approved to lower A1c in type 2 diabetes, and both do it well. In a direct head-to-head diabetes trial (SURPASS-2), tirzepatide lowered A1c more than semaglutide at the doses studied, with the top tirzepatide dose reaching roughly a 2.3% reduction versus about 1.9% for semaglutide 1 mg. For someone whose main goal is blood sugar control, both are strong choices, and the difference, while real, is smaller than the weight difference below. The right pick also depends on other medications, kidney function, and what your plan covers.
Weight loss: Mounjaro takes off more
Even though neither is approved for obesity, weight loss is the reason many people ask about Ozempic vs Mounjaro. In their diabetes trials, tirzepatide produced more weight loss than semaglutide, roughly 11 kg versus about 6 kg in the head-to-head, and the gap is wider at higher doses. The same pattern holds for their weight-management twins, Zepbound and Wegovy, where tirzepatide reached about 20.9% versus semaglutide's 14.9%. The full breakdown by drug is in our GLP-1 weight loss results index, and the dedicated weight brands are compared in Wegovy vs Zepbound.
GLP-1 results index
Average weight loss by drug
Mean weight loss in each drug's pivotal obesity trial, over 56 to 72 weeks.
Cost: similar, and route-dependent
List prices are close, around $997 a month for Ozempic and $1,069 for Mounjaro, and neither has a dedicated cash-vial program the way the weight brands do. For people without coverage, the routes to a lower price run through insurance, manufacturer savings cards (for the commercially insured), pharmacy discount cards, and patient assistance. Because both are diabetes drugs, coverage tends to be easier than for the weight-loss brands. The full route-by-route picture is in our GLP-1 Cost Index and cost without insurance guide.
GLP-1 cost index
What a GLP-1 costs per month, by route
The same class of medicine spans more than tenfold depending on how you pay.
Side effects: similar, GI-led
Ozempic vs Mounjaro is close to a tie on tolerability. Both share the same main side effects, which are gastrointestinal and concentrated early and during dose increases.
| Side effect | Ozempic | Mounjaro |
|---|---|---|
| Nausea | Common, early | Common, early |
| Diarrhea / constipation | Common | Common |
| Low blood sugar | Low risk alone; higher if combined with insulin or sulfonylureas | |
| Boxed warning | Thyroid C-cell tumor warning (rodent data); avoid with personal/family history of medullary thyroid cancer or MEN2 | |
Most side effects fade as the body adjusts and are eased by slow titration and smaller, lower-fat meals. See our GLP-1 side effects timeline and managing nausea on GLP-1.
Beyond blood sugar: heart and kidney
For people with type 2 diabetes, the choice is not only about A1c and weight. Semaglutide, the molecule in Ozempic, has established evidence for reducing the risk of major cardiovascular events in people with type 2 diabetes and heart disease, plus a growing body of data on protecting kidney function. Its weight-management sibling, Wegovy, carries a formal cardiovascular approval. Tirzepatide, the molecule in Mounjaro, is newer, and its dedicated cardiovascular outcomes trials are still maturing, so the long-term heart and kidney evidence is not yet as deep even though it controls blood sugar and weight at least as well. For a younger person focused on weight and A1c, that gap may not matter; for an older patient with established heart or kidney disease, the longer evidence base behind semaglutide can tip the decision. This is the kind of trade-off a clinician weighs against your full history, rather than a simple question of which drug is stronger.
Availability and switching
Both drugs have seen supply pressure as demand surged, though availability has improved as manufacturing scaled up. If one is hard to fill, your clinician and pharmacy can advise on the other or on the weight-approved twins. Switching between them is common, but you do not match doses milligram for milligram, because they are different molecules on different titration schedules, so a clinician sets the right starting dose on the new drug. Whichever you land on, consistency matters more than the brand: reaching and staying on an effective dose, paired with protein and activity, is what drives the result.
Using Ozempic or Mounjaro for weight loss
Because both are diabetes drugs, using either purely for weight loss is off-label, and the on-label weight versions are Wegovy (semaglutide) and Zepbound (tirzepatide). In practice, people end up on Ozempic or Mounjaro for weight because of cost, supply, or what a clinician will prescribe. If weight is the goal and you have the choice, the weight-approved brands are the cleaner route, both for dosing designed around weight and for the dedicated cash programs. We cover how to access these in how to get GLP-1 online and who qualifies in who qualifies for a GLP-1 prescription.
Which should you choose?
- Blood sugar control: both are strong; Mounjaro edges ahead on A1c in the head-to-head.
- Weight loss: Mounjaro (tirzepatide) takes off more in studies.
- Track record: Ozempic has been in wide use longer.
- Cost and coverage: compare your specific plan; both are diabetes-covered more readily than weight brands.
- Weight-only goal: consider the on-label twins, Wegovy or Zepbound, instead.
This is a prescription decision for you and a clinician who knows your diabetes, kidney function, and other medications. For the weight-brand versions, see Wegovy vs Zepbound and Mounjaro vs Zepbound.
Scientific References
5 sources- 1
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 387(3) · 2022PMID: 35658024
NEJM - 2
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
NEJM - 3
Frías JP, Davies MJ, Rosenstock J, et al.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
New England Journal of Medicine · 2021
NEJM - 4
Drucker DJ
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Cell Metabolism · 27(4) · 2018PMID: 29617641
PubMed - 5
U.S. Food and Drug Administration
Ozempic and Mounjaro prescribing information
U.S. Food and Drug Administration · 2024
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is Ozempic or Mounjaro better for weight loss?
Mounjaro (tirzepatide) tends to produce more weight loss than Ozempic (semaglutide). In their diabetes trials the head-to-head showed roughly 11 kg versus about 6 kg, and the same pattern holds for their weight-loss twins, Zepbound and Wegovy. Neither Ozempic nor Mounjaro is FDA-approved for weight loss, though both are used off-label for it.
Are Ozempic and Mounjaro the same drug?
No. Ozempic is semaglutide, which activates the GLP-1 receptor. Mounjaro is tirzepatide, which activates both the GLP-1 and the GIP receptor. They are different molecules from different manufacturers, which is why Mounjaro tends to lower blood sugar and weight more.
Which lowers A1c more, Ozempic or Mounjaro?
In a direct head-to-head diabetes trial, tirzepatide (Mounjaro) lowered A1c more than semaglutide (Ozempic), with the top dose reaching roughly a 2.3% reduction versus about 1.9% for semaglutide 1 mg. Both are strong choices for blood sugar; the difference is real but smaller than the weight-loss gap.
Is Ozempic or Mounjaro cheaper?
Their list prices are close, around $997 a month for Ozempic and $1,069 for Mounjaro. Neither has a dedicated manufacturer cash-vial program like the weight brands. What you pay depends on insurance, savings cards, discount cards, or patient assistance, and coverage is generally easier for diabetes use than for weight loss.
Can you switch from Ozempic to Mounjaro?
Many people switch, often for better blood sugar control or more weight loss, but it should be done with a clinician who sets the right starting dose on the new drug. You do not match milligrams directly, because they are different molecules with different dosing schedules.
Should I use Ozempic or Mounjaro just for weight loss?
Both are diabetes drugs, so using either purely for weight is off-label. If weight loss is the goal and you have the choice, the on-label twins, Wegovy (semaglutide) and Zepbound (tirzepatide), are usually the cleaner route, with dosing designed for weight and dedicated cash-pay programs. Discuss the options with a clinician.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.